Louis A. Bianco - Co-Founder, Principal Financial Officer, Principal Accounting Officer, Executive Vice President - Finance and Administration and Secretary Steven E. Benner - Chief Medical Officer and Executive Vice President Analysts Michael G. King - Rodman & Renshaw, LLC, Research Division PresentationOperator Ladies and gentlemen, thank you for standing by. Welcome to the Cell Therapeutics Q2 Financial Results Call on the 1st of August, 2012. [Operator Instructions] I would now like to hand the conference over to Dr. James Bianco, President and CEO. Please go ahead, sir. James A. Bianco Good morning. Thank you for joining us today. Before I get started, I'd like to remind you, as is common with presentations of this type, that we'll be making forward-looking statements, and as such, I recommend you refer to our SEC filings for more information on the company. Let me also remind you that this call is recorded and be available for playback on our website. Any unauthorized recording of this call or use of this recording is prohibited without written consent of the company. So on today's call, we're going to review the financial results for the second quarter, update you on our prelaunch activities and in-market research on a potential commercial opportunity on Pixuvri, talk about the status of the pacritinib Phase III program and review the strategy for tosedostat and briefly discuss the activities on OPAXIO and brostallicin. Let me start with the financial results for the second quarter.